A nutritional powder containing oligopeptide includes the following components by weight: oligopeptide powder 55-80%, fruit powder 5-30%, amino acid powder 0.5-5%, multivitamin powder 1.25-5%, mineral powder 0.25-3%, and compound sweetener powder 5-10%.

Dimethyl sulfone may be used in the treatment of heat stress in poultry by oral administration, wherein the dimethyl sulfone is administered to chronically heat stressed poultry. The poultry may be exposed to a temperature of more than 27° C., or at least 30° C., optionally for at least 5 hours a day. The poultry may be exposed to a relative air humidity of at least 40% on average. The dimethyl sulfone is administered to poultry in a starter, grower, and/or finisher phase.

Dimethyl sulfone may be used in the treatment of heat stress in poultry by oral administration, wherein the dimethyl sulfone is administered to chronically heat stressed poultry. The poultry may be exposed to a temperature of more than 27° C., or at least 30° C., optionally for at least 5 hours a day. The poultry may be exposed to a relative air humidity of at least 40% on average. The dimethyl sulfone is administered to poultry in a starter, grower, and/or finisher phase.

The present invention relates to isolated monoclonal antibodies (mAbs) and/or antigen-binding fragments thereof that specifically recognize indoxyl sulfate, a protein-bound uremic toxin, and uses of such isolated anti-IS mAbs and/or antigen-binding fragments thereof to create immunoassay methods applied in theragnosis of IS-related diseases.

The present invention relates to isolated monoclonal antibodies (mAbs) and/or antigen-binding fragments thereof that specifically recognize indoxyl sulfate, a protein-bound uremic toxin, and uses of such isolated anti-IS mAbs and/or antigen-binding fragments thereof to create immunoassay methods applied in theragnosis of IS-related diseases.

L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).

A compound which is either A: ##STR00001##
or B: ##STR00002##
and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.

The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.